Neumora Therapeutics(NMRA) - 2024 Q2 - Quarterly Results

EXHIBIT 99.1 Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and Alzheimer's disease agitation, providing opportunity for multiple value-creating catalysts over next 18 months Strong financial position with $371.6 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WA ...